title: Effect of amiloride and spironolactone on renal tubular function, ambulatory blood pressure, and pulse wave velocity in healthy participants in a double-blinded, randomized, placebo-controlled, crossover trial.
abstract: We wanted to test the hypothesis that treatment with amiloride or spironolactone reduced ambulatory (ABP) and central blood pressure (CBP) and that tubular transport via ENaCγ and AQP2 was increased after furosemide treatment. During baseline conditions, there were no differences in ABP, CBP, renal tubular function, or plasma concentrations of vasoactive hormones. After furosemide treatment, an increase in CBP, CH(2)o, FE(Na), FE(K), u-AQP2/min, u-ENaCγ/min, PRC, p-Ang II, and p-Aldo was observed. The increases in water and sodium absorption via AQP2 and ENaC after furosemide treatment most likely are compensatory phenomena to antagonize water and sodium depletion.
authors.affiliation: Department of Medical Research, Holstebro Hospital and University of Aarhus, Holstebro, Denmark. Solveig.Klok.Matthesen@vest.rm.dk
authors.forename: Solveig Klok
authors.initials: SK
authors.lastname: Matthesen
authors.forename: Thomas
authors.initials: T
authors.lastname: Larsen
authors.forename: Thomas Guldager
authors.initials: TG
authors.lastname: Lauridsen
authors.forename: Henrik
authors.initials: H
authors.lastname: Vase
authors.forename: Pia Holland
authors.initials: PH
authors.lastname: Gjørup
authors.forename: Karen Marie
authors.initials: KM
authors.lastname: Nykjær
authors.forename: Søren
authors.initials: S
authors.lastname: Nielsen
authors.forename: Erling Bjerregaard
authors.initials: EB
authors.lastname: Pedersen
mesh_terms: D000293:Adolescent; D000328:Adult; D000465:Algorithms; D000584:Amiloride / Q000494:pharmacology*; D051399:Aquaporin 2 / Q000652:urine; D015415:Biomarkers / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory / Q000379:methods; D018592:Cross-Over Studies; D004232:Diuretics / Q000494:pharmacology*; D004311:Double-Blind Method; D053503:Epithelial Sodium Channels / Q000187:drug effects; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D063177:Pulse Wave Analysis; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000494:pharmacology*
chemical_list: D051399:Aquaporin 2; D015415:Biomarkers; D004232:Diuretics; D053503:Epithelial Sodium Channels; D013148:Spironolactone; D000584:Amiloride